Literature DB >> 32284317

The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia.

Justin M Watts1, Terrence Bradley2.   

Abstract

Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve disease-free and overall survival in adult patients in China up to age 55, particularly in patients with intermediate cytogenetic risk.See related article by Wei et al., p. 3154. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32284317      PMCID： PMC9291266          DOI： 10.1158/1078-0432.CCR-20-0462

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  5 in total

1.  Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia.

Authors:  Hui Wei; Ying Wang; Robert Peter Gale; Dong Lin; Chunlin Zhou; Bingcheng Liu; Shaowei Qiu; Runxia Gu; Yan Li; Xingli Zhao; Shuning Wei; Benfa Gong; Kaiqi Liu; Xiaoyuan Gong; Yuntao Liu; Guangji Zhang; Zhen Song; Yang Wang; Wei Li; Yingchang Mi; Jianxiang Wang
Journal:  Clin Cancer Res       Date:  2020-02-06       Impact factor: 12.531

2.  Cytarabine dose for acute myeloid leukemia.

Authors:  Bob Löwenberg; Thomas Pabst; Edo Vellenga; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Bart J Biemond; Alois Gratwohl; Georgine E de Greef; Leo F Verdonck; Martijn R Schaafsma; Michael Gregor; Matthias Theobald; Urs Schanz; Johan Maertens; Gert J Ossenkoppele
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

3.  High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

Authors:  Roelof Willemze; Stefan Suciu; Giovanna Meloni; Boris Labar; Jean-Pierre Marie; Constantijn J M Halkes; Petra Muus; Martin Mistrik; Sergio Amadori; Giorgina Specchia; Francesco Fabbiano; Francesco Nobile; Marco Sborgia; Andrea Camera; Dominik L D Selleslag; Francois Lefrère; Domenico Magro; Simona Sica; Nicola Cantore; Meral Beksac; Zwi Berneman; Xavier Thomas; Lorella Melillo; Jose E Guimaraes; Pietro Leoni; Mario Luppi; Maria E Mitra; Dominique Bron; Georges Fillet; Erik W A Marijt; Adriano Venditti; Anne Hagemeijer; Marco Mancini; Joop Jansen; Daniela Cilloni; Liv Meert; Paola Fazi; Marco Vignetti; Silvia M Trisolini; Franco Mandelli; Theo de Witte
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

4.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.

Authors:  R J Mayer; R B Davis; C A Schiffer; D T Berg; B L Powell; P Schulman; G A Omura; J O Moore; O R McIntyre; E Frei
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245

5.  High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis.

Authors:  Wei Li; Xiaoyuan Gong; Mingyuan Sun; Xingli Zhao; Benfa Gong; Hui Wei; Yingchang Mi; Jianxiang Wang
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240
  5 in total
  1 in total

1.  Dexamethasone Sensitizes Acute Monocytic Leukemia Cells to Ara-C by Upregulating FKBP51.

Authors:  Huanxin Sun; Xiaowen Liu; Laicheng Wang; Bin Cui; Wenli Mu; Yu Xia; Shuang Liu; Xin Liu; Yulian Jiao; Yueran Zhao
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.